MGDs are not a new concept – established blood cancer drugs Bristol-Myers ... San Diego, California-based Neomorph was set up in 2020 by investment group Deerfield Management, coming out of ...

Biogen and Neomorph have entered a research partnership aimed at discovering and developing molecular glue degraders for the ...

NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular ...

AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and immunology, with the deal worth $1.64bn. The collaboration and ...

Neomorph will receive an undisclosed upfront ... based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer, in a deal worth more than $1 billion. Back in December, AbbVie ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform.

SAN DIEGO, Jan. 14, 2025 /PRNewswire/ -- Neomorph, Inc., today announced the appointment of Dr. Klaus Wagner as Chief Medical Officer. Dr. Wagner is a seasoned biotech executive with extensive ...

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is ...